BTSG vs. OPCH: Which Home Infusion Stock is a Better Buy Now?

BrightSpring Health Services (BTSG) is highlighted as a more compelling investment than Option Care Health (OPCH) within the expanding home infusion and specialty pharmacy sector, driven by superior growth and valuation. BTSG reported 33% Q1 revenue growth in its infusion segment, significantly outpacing OPCH's 16% overall revenue increase, and projects an 82.1% rise in 2025 EPS compared to OPCH's 36.6%. Despite OPCH's strategic investments in AI and automation for efficiency, BTSG's faster top-line and earnings growth, coupled with a more attractive forward price-to-sales multiple of 0.31x versus OPCH's 0.90x, positions it as a Zacks Rank #2 'Buy' against OPCH's 'Hold' rating.

Analysis

The home infusion and specialty pharmacy sector is experiencing a secular shift toward decentralized care, creating a competitive environment where BrightSpring Health Services (BTSG) and Option Care Health (OPCH) are employing distinct growth strategies. BTSG is demonstrating aggressive top-line expansion, evidenced by a 33% year-over-year revenue increase in its infusion segment in Q1, driven by a 20% rise in script volume. This performance led management to raise its full-year 2025 revenue and EBITDA guidance, with adjusted EBITDA now projected to grow up to 27%. In contrast, OPCH is pursuing a more measured growth path, posting a 16% revenue increase and focusing on operational leverage through its partnership with Palantir to deploy AI and RPA for margin improvement. While OPCH's strategy is sound, generating a 13.7% rise in adjusted EBITDA and funding a $100 million stock repurchase, its growth metrics are significantly outpaced by BTSG. The valuation differential is stark: BTSG trades at a forward price-to-sales multiple of 0.31x, while OPCH trades at 0.90x. This substantial valuation discount, coupled with a projected 2025 EPS growth of 82.1% for BTSG versus 36.6% for OPCH, frames BTSG as the higher-growth, more attractively priced asset in this direct comparison.

Key Decisions for Investors

• Investors seeking growth at a reasonable price should consider BrightSpring Health Services (BTSG), which offers superior revenue and projected EPS growth (82.1% in 2025) at a significantly lower forward price-to-sales multiple of 0.31x compared to its peer.
• For those holding Option Care Health (OPCH), its stable mid-teens revenue growth, focus on AI-driven margin expansion, and consistent capital returns provide a basis for maintaining the position, though its growth trajectory appears more moderate.
• Closely monitor the execution of both companies' strategies, specifically tracking if BTSG can sustain its high script volume and if OPCH’s AI initiatives translate into meaningful margin expansion beyond the current 8.4% EBITDA margin, as this will be key to validating their respective investment theses.